We have collected information about Molecular Targeting And Gene Delivery In Bladder Cancer Therapy for you. Follow the links to find out details on Molecular Targeting And Gene Delivery In Bladder Cancer Therapy.
https://www.researchgate.net/publication/51438616_Molecular_targeting_and_gene_delivery_in_bladder_cancer_therapy
Molecular targeting and gene delivery in bladder cancer therapy G.E. V outsinas 1 , D.J. Stravopodis 2 1 Laboratory of Environmental Mutagenesis and Carcinogenesis, Institute of Biology , NCSR ...
https://link.springer.com/chapter/10.1007%2F978-3-319-64769-2_9
Sep 18, 2017 · With the recent approval of immune checkpoint inhibitor therapy for advanced bladder cancer, more attention is now being paid to therapeutic needs and opportunities in this disease. This, coupled with advances in molecular characterization of bladder cancer, presents a great opportunity for drug development and the rational integration of targeted agents in the care of bladder cancer patients.Author: Elizabeth R. Kessler, Elizabeth R. Kessler, Dan Theodorescu, Dan Theodorescu, Thomas W. Flaig, Thoma...
https://www.sciencedirect.com/science/article/pii/S1773224719320258
Bladder cancer is a severe disease that threatens human health. The high recurrence rate and severe side-effects of traditional bladder cancer therapy require more efficient and higher targeting treatment. Drug delivery systems especially being endowed with the targeting property may provide a feasible means to solve such problems.Author: Kun Yu, Meiping Liu, Hong Dai, Xiao Huang
https://advances.sciencemag.org/content/5/9/eaaw6499.full
Sep 01, 2019 · In the present study, we showed that natural halloysite nanotube (HNT)–assisted delivery of an active small interfering RNA (siRNA) targeting receptor-interacting protein kinase 4 ( RIPK4 ) efficiently silenced its expression to treat bladder cancer.Author: Jianye Liu, Yi Zhang, Qinghai Zeng, Hongliang Zeng, Xiaoming Liu, Pei Wu, Hongyi Xie, Leye He, Zhi L...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721287/
Another gene therapy viral vector, which might be used in the delivery of a normal TP53 gene in bladder cancer cells, involves the selectively replicating adenovirus dl1520 (ONYX-015) (Heise et al 1997). Deletion of the E1B 55 kDa protein gene from the viral genome results in selective replication of cells that lack a functional p53 pathway.Author: Matteo Fassan, Edouard J Trabulsi, Leonard G Gomella, Raffaele Baffa
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063594/
The unphosphorylated pRb inhibits progression from the G1 to S phase of the cell cycle.68 The p53 protein is a tumor suppressor, and the gene coding for p53 is mutated in >50% of all cancers.69 The p53 pathway is disrupted in invasive bladder cancer and has been correlated with poor clinical outcome, progression to invasive from noninvasive bladder cancer, and resistance to radiation therapy…Author: Dmitriy Smolensky, Kusum Rathore, Maria Cekanova
Searching for Molecular Targeting And Gene Delivery In Bladder Cancer Therapy?
You can just click the links above. The data is collected for you.
